| [Objective] To investigate the safety and efficacy of carrelizumab combined with first-line chemotherapy in the treatment of EGFR/ALK mutation-negative non-squamous cell lung cancer(NSCLC).[Methods] A total of 44 patients with advanced/metastatic non-squamous cell lung cancer admitted to our hospital from October 2019 to October 2020 were collected and divided into control group and observation group according to random number table.Among them,22 cases were treated with carrelizumab combined with chemotherapy,and 22 cases were treated with chemotherapy alone.The control group was given conventional chemotherapy regimen,and on the first day of each cycle,500mg/m2 of pemetrexed and 75mg/m2 of cisplatin/carboplatin were given intravenous injection,with an AUC of 5-6,for 21 days.In the experimental group,200 mg carrelizumab was added to the chemotherapy group,intravenously injected on the first day of each cycle,given once every 21 d,observed for more than 4 cycles,and evaluated every 2 cycles,and observed for efficacy and adverse reactions.[Results] The objective response rate(ORR),disease control rate(DCR)and median progression-free survival(MPFS)in the experimental group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of serum CEA and CYRFA21-1 in experimental group were lower than those in control group before and after treatment(P < 0.05).The levels of CD3+,CD4+ and CD4+ /CD8+ in the experimental group were higher than those in the control group,and the levels of CD8+ were lower than those in the control group,with statistical significance(P < 0.05).There were no significant differences in adverse reactions such as decreased appetite,fatigue,anemia and diarrhea between the experimental group and the control group(P<0.05).However,in the experimental group,reactive capillary hyperplasia(RCCEP),immune-associated pneumonia,immune-associated liver injury and other immunorelated adverse reactions were special and specific.[Conclusion] In the treatment of advanced/metastatic non-squamous non-small cell lung cancer,the effect of carrelizumab combined with chemotherapy is significantly better than that of chemotherapy alone,and the immune function is improved.The curative effect was increased but the toxic reaction was not increased and the safety was acceptable.However,the specific reactions of RCCEP,immune-associated pneumonia and immune-associated liver function injury should be paid more attention. |
